Navigation Links
Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations
Date:12/4/2008

AMSTERDAM, December 4 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today that it has successfully completed treatment of the last patient on its ATIR(TM) phase I/II clinical trial. ATIR(TM), a donor lymphocyte cell based product, is under development to prevent acute Graft versus Host Disease (GvHD) and allow early immune reconstitution following a mismatched bone marrow transplantation. Nineteen end stage blood cancer patients were treated with no cases of grade III/IV acute GvHD occurring within the first 100 days after ATIR(TM) infusion, showing the feasibility and tolerability of the addition of ATIR(TM) in combination with a mismatched transplant procedure.

Following scientific advice from the EMEA Kiadis Pharma is preparing to initiate a multi center multinational pivotal study starting recruitment early 2009. In this study the efficacy of ATIR(TM) will be investigated in patients diagnosed with AML, ALL or MDS eligible for an allogeneic bone marrow transplantation but for whom no matching donor is available.

"Bone marrow transplantations are often the only treatment option left for end-stage blood cancer patients. But too many patients simply do not find a suitable matched donor in time" says Dr. Denis-Claude Roy of the Maisonneuve-Rosemont Hospital in Montreal, the principal investigator on the study. "Our study shows a rapid immune reconstitution in transplanted patients provided with ATIR(TM) treated immune cells from mismatched donors. Without ATIR(TM) treatment this would not be possible because of the high risk of acute Graft versus Host Disease with mismatched donor immune cells. This is obviously a very hopeful development for a large patient group."

Dr. Manja Bouman, CEO of Kiadis Pharma, says "The results of this clinical trial are very encouraging and it is another important milestone in the development of ATIR(TM) as a novel approach which may enable a safe an
'/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
2. Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
3. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
4. Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand
5. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
6. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
7. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
8. Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
9. Isogen Launches Major New Facility to Address Global Biopharma Demand
10. Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia
11. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... MARLBOROUGH, Mass. , Aug. 30, 2014 /PRNewswire/ ... from its NEural Cardiac TherApy foR Heart Failure ... sham-controlled clinical trial investigating vagus nerve stimulation (VNS) ... Zannad, M.D., Ph.D., Professor of Therapeutics and Cardiology ... the Institut National de la Sante et de ...
(Date:8/29/2014)... 2014  Chuma Holdings, Inc. (OTCBB:CHUM) (the "Company"), ... support services for the lawfully organized cannabis industry, ... approved the Company,s name and symbol change request. ... be known as Chuma Holdings, Inc. ... merger with the Company,s wholly-owned subsidiary, Chuma Holdings, ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- SAM ... (Axilla) Strap for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today that ... recall to address a potential issue with a ... for the Axilla application of the SAM Junctional ...
Breaking Medicine Technology:Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2
... Inc. (NYSE: ZMH ; SIX: ZMH) announced today that ... unsecured notes in an underwritten public offering consisting of $500.0 ... 5.75% notes due 2039. The 10-year notes were priced to ... 30-year notes were priced at 135 basis points above their ...
... Research presented at the American College of Allergy, Asthma ... intervention to reduce over-dispensing and waste of asthma medications ... in substantial cost savings. , Medco Health Solutions, Inc. ... study that examined the effectiveness and safety of a ...
Cached Medicine Technology:Zimmer Holdings, Inc. Agrees to Sell $1 Billion of Senior Notes 2New Research Shows Over-use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist-initiated Physician Intervention 2New Research Shows Over-use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist-initiated Physician Intervention 3
(Date:9/1/2014)... (PRWEB) September 01, 2014 Bioinformatics ... organize and analyze biological and genetic data. A ... activity of developing software tools to generate and ... be confused with biological computation. While bioinformatics simply ... of biology can its related concepts, biological computation ...
(Date:9/1/2014)... 2014 Top10BestSEOHosting.com has recently compared ... host suppliers carefully, Top10BestSEOHosting.com is here to announce ... web hosting suppliers in 2014. , JustHost ( ... a top-of-the-line shared hosting plan. The company’s approach ... that is affordable, accessible and powerful enough for ...
(Date:9/1/2014)... 01, 2014 AttorneyOne.com, a recognized authority ... latest information from the FDA on DePuy Synthes ... announced on August 28, that specific lots of DePuy ... I) as the device may reverse directions after surgery. ... (CMF) Distraction System is an implant used to lengthen ...
(Date:9/1/2014)... Mahwah, NJ (PRWEB) September 01, 2014 ... disorder (NEAD) is a psychological disorder that can have ... look very much like epileptic seizures however, they are ... rather by emotional triggers. It is estimated that ... than those affected by multiple sclerosis. , ...
(Date:8/31/2014)... 31, 2014 MedixSafe has become very ... and narcotics lockers . Electronic Security ... brand for distribution worldwide. “We have now shipped multiple ... McCollum, MedixSafe Sales Manager , MedixSafe is a division ... and network cabling company with over 30 years in ...
Breaking Medicine News(10 mins):Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2Health News:Memphis-based Electronic Security Specialists Now Offers MedixSafe Narcotics Cabinets Internationally 2Health News:Memphis-based Electronic Security Specialists Now Offers MedixSafe Narcotics Cabinets Internationally 3
... June 16 The famed nonprofit Los Angeles,Jewish Home ... program designed to address one of the major health ... Jewish Community Foundation,the largest manager of charitable assets for ... prevention and fitness program becomes part of the care,the ...
... 2008 Researchers at Ben-Gurion University of the Negev ... recognition system, tested at a Washington, D.C. hospital, that ... by motioning instead of touching a screen, keyboard or ... to a just released article. , The June article," ...
... from the Swedish medical university Karolinska Institute (KI) suggests that ... on if adults decide to have sex with persons of ... the individual,s unique experiences have the strongest influence on our ... in the world so far and was performed in collaboration ...
... injury-related deaths, the gap between black and white American ... at the Johns Hopkins Bloomberg School of Public Health. ... deaths among blacks ages 15 to 24 decreased, while ... in the June, 2008, edition of Injury Prevention ...
... partners, innovative use of Microsoft technology to exceed ... customer expectations and solve business problems., ... delivered exemplary solutions to customers, Microsoft Corp. today,announced ... Partner of the,Year Awards. The awards honor Microsoft ...
... PLM Based on Dassault Systemes, Newly,Introduced V6 Platform and Intercim,s ... ... PAUL, Minnesota, June 16 Intercim LLC, a global,leader in ... regulated industries and Dassault,Systemes (DS) (Nasdaq: DASTY; Euronext Paris: #13065, ...
Cached Medicine News:Health News:Los Angeles Jewish Home Institutes New Fall Prevention Program With Jewish Community Foundation Grant 2Health News:Los Angeles Jewish Home Institutes New Fall Prevention Program With Jewish Community Foundation Grant 3Health News:Gesture interface device developed by Ben-Gurion University of the Negev 2Health News:Racial disparities reduced in injury related mortality 2Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 2Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 3Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 4Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 5Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 6Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 7Health News:Intercim and Dassault Systemes Sign Memorandum of Understanding 2Health News:Intercim and Dassault Systemes Sign Memorandum of Understanding 3
The electrically active helix of CapSureFix Novus lead is designed to extend easily for active fixation and retract for venous passage....
Steroid eluting pacemaker leads...
... Streamline family of temporary sensing and pacing ... standard in temporary pacing leads and improved ... to use and less traumatic to heart ... Temporary Pacing Lead is designed for temporary ...
VascoStim B 2/5F is a bipolar temporary pacing lead with a balloon. It can be placed easily by the resistance of the inflated balloon in the blood flow....
Medicine Products: